BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 16, 2026
Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
Immuno-oncology RSS Feed RSS

Lab glassware and antibodies art concept
Immune

Probing bidirectional cancer-autoimmune link can yield new targets

Dec. 16, 2024
By Anette Breindl
Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s Office of Autoimmune Disease Research and Office of Research in Women’s Health earlier this month. Cancer, that line of reasoning goes, arises when the immune system is not good enough at recognizing harmful autoantigens. Autoimmunity arises when it is hypervigilant, mistaking harmless autoantigens for problematic ones and going on the attack.
Read More
Test tubes, dropper
Immuno-oncology

Elevation Oncology nominates HER3 ADC as development candidate

Dec. 13, 2024
Elevation Oncology Inc. has nominated EO-1022 as its HER3 antibody-drug conjugate (ADC) development candidate for the treatment of solid tumors that express HER3.
Read More
Immuno-oncology

UB-VV111 shows favorable safety, low risk of off-target transduction

Dec. 13, 2024
To address the existing challenges with CAR T-cell therapy, scientists at Umoja Biopharma Inc. developed the Vivovec platform, which is an off-the-shelf surface-engineered lentiviral vector (LVV) drug product designed to generate CAR T cells in vivo without lymphodepletion by selectively binding, activating and transducing T cells.
Read More
Scientist in lab with microscope
Immuno-oncology

Gram-negative bacteria platform offers multiple immune receptor agonists for tumor immunotherapy

Dec. 12, 2024
Previous research suggested that gram-negative bacteria may hold potential for cancer immunotherapy because they contain agonists for multiple immune receptors.
Read More
Immuno-oncology

Cancervax selects PDAC as target indication using universal cancer treatment platform

Dec. 12, 2024
Cancervax Inc. has selected pancreatic ductal adenocarcinoma (PDAC) as one of its first targets for preclinical development using its novel universal cancer treatment (UCT) platform.
Read More
Immuno-oncology

Polypid brings PLEX technology to STING agonist collaboration with Immunogenesis

Dec. 12, 2024
Polypid Ltd. has entered into a new research and development collaboration with Immunogenesis Inc. for the development of novel formulations utilizing Polypid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology and Immunogenesis’ potent STING agonist drug candidate to potentially enhance treatment for solid tumors.
Read More
Immuno-oncology

KITE-753, a rapid manufactured CAR T therapy with superior antitumor efficacy and enhanced expansion in vivo

Dec. 12, 2024
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell therapy being developed for the treatment of B-cell malignancies.
Read More
Immuno-oncology

Pilatus Biosciences’ PLT-012 awarded orphan drug designation

Dec. 11, 2024
Pilatus Biosciences Inc.’s PLT-012 has been awarded orphan drug designation by the FDA for treating liver and intrahepatic bile duct cancer.
Read More
Antibody-drug conjugate illustration
Immuno-oncology

FDA clears IND for B7-H4-targeting ADC

Dec. 11, 2024
Nextcure Inc. has reported IND clearance from the FDA enabling initiation of a phase I trial of LNCB-74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed for various cancers.
Read More
Immuno-oncology

Sichuan Kelun-Biotech divulges new HER2-targeting ADCs

Dec. 10, 2024
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized antibody-drug conjugates.
Read More
Previous 1 2 … 50 51 52 53 54 55 56 57 58 … 1000 1001 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 16, 2026.
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing